Questionnaire – Monoclonal Antibody Development against a Peptide

Please fill out this form as a prerequisite for planning and specifying the major steps of the respective project.

It will also be used as the basis for quotation and further discussion of project details.

All information provided including the client information at the end of this questionnaire will be treated strictly confidential. A nondisclosure agreement can be signed upon request.

1. Antigen Information - Peptide

Peptide has to be synthesized: ☐ Yes ☐ No

If yes, please answer the following questions:

Prediction of epitopes of the amino acid Sequence requested? ☐ Yes ☐ No

Accession number of the protein: _____

If the peptide is (commercially) available, please specify the following information:

Sequence of the peptide: _____

Peptide is synthesized as: ☐ Amide ☐ Free acid

Requested purity (>95% is recommended): _____

Is the parental protein from which the peptide is derived available? ☐ Yes ☐ No

Is the peptide/protein available in buffer? ☐ Yes ☐ No

If yes, please answer the following questions:

Availability of the peptide/protein in buffer: ☐ Soluble ☐ Precipitated

BioGenes GmbH
Koepenicker Str. 325, 12555 Berlin, Germany
Phone: +49 (0)30 6576 2396
Email: service@biogenes.de

Does the buffer contain a preservative? (We do not recommend the use of preservatives)

☐ No ☐ Yes, please specify the preservative: _____

2. Antibody Development in Mouse

Should cross-reactivities be included?

☐ Yes ☐ No ☐ I am not sure yet

If yes, please indicate the kind of selection:

☐ Positive ☐ Negative ☐ Cross-reactivity test for characterization only

Are cross-reactants (commercially) available? ☐ Yes ☐ No

Name: _____

Purity [%]: _____

Molecular weight [kDa]: _____

Cross-reactants are available in buffer: ☐ Soluble ☐ Precipitated

Is further information about cross-reactants available (please provide)?

_____

Biosafety level: ☐ **1** ☐ **2**

If the cross-reactant is a genetically modified organism, please specify:

_____

For BSL2 (biosafety level 2 according to Biological Agents Ordinance https://www.gesetze-im internet.de/englisch_biostoffv/englisch_biostoffv.pdf please provide risk analysis.

If samples submitted are GMO, please attach Formblatt Z or relevant documentation. The final risk assessment and security level for GMO organisms will be finalized by Biogenes in accordance with the German law since regional differences may occur. (Genetic Engineering Safety Ordinance – GenTSV) https://www.bmleh.de/SharedDocs/Gesetzestexte/EN/GenTSV-E-en.html

BioGenes GmbH
Koepenicker Str. 325, 12555 Berlin, Germany
Phone: +49 (0)30 6576 2396
Email: service@biogenes.de

3. Antibodies to be used in

Western Blot	☐ Yes	☐ No	☐ I am not sure yet
ELISA	☐ Yes	☐ No	☐ I am not sure yet
Immunohistochemistry	☐ Yes	☐ No	☐ I am not sure yet
Immunofluorescence assay (IFA)	☐ Yes	☐ No	☐ I am not sure yet
Immunoassay development	☐ Yes	☐ No	☐ I am not sure yet

Other, please specify: _____

4. Preparation of cell culture supernatant for testing

Should preservatives be added prior to cell culture supernatant shipment?

☐ No ☐ Yes, please add the following:

☐ NaN3 ☐ 0.2 µm filtrated ☐ ProClin ☐ Not filtrated

☐ Other, please specify: _____

BioGenes GmbH
Koepenicker Str. 325, 12555 Berlin, Germany
Phone: +49 (0)30 6576 2396
Email: service@biogenes.de

5. Do you require further Mab-related services from BioGenes?

Modification:

☐ Yes ☐ No

If yes, please specify: _____

Production:

☐ Yes ☐ No

Pair search (capture/detector):

☐ Yes ☐ No

Immunoassay development:

☐ Yes ☐ No

If yes, please specify type: _____

Determination of affinity constants:

☐ Yes ☐ No

Storage of cryo cultures at Biogenes:

☐ Yes ☐ No

☐ With taking care ☐ Without taking care

Sequencing of hybridoma cells at BioGenes:

☐ Yes ☐ No

BioGenes GmbH
Koepenicker Str. 325, 12555 Berlin, Germany
Phone: +49 (0)30 6576 2396
Email: service@biogenes.de

6. Please provide additional information on:

Planned timelines: _____

Payment planned directly or via a purchasing platform (e.g. Scientist.com):

_____

How did you find out about BioGenes? _____

Other information not previously covered: _____

Client Information:

Company/Institution name: _____

Contact person: _____

Address: _____

_____

_____

Phone: _____

Email: _____

Date: _____

BioGenes GmbH
Koepenicker Str. 325, 12555 Berlin, Germany
Phone: +49 (0)30 6576 2396
Email: service@biogenes.de